<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450878</url>
  </required_header>
  <id_info>
    <org_study_id>I09002 FRETEP</org_study_id>
    <nct_id>NCT01450878</nct_id>
  </id_info>
  <brief_title>Renal Graft Function After Treatment With Erythropoietin (EPO)</brief_title>
  <acronym>FRETEP</acronym>
  <official_title>Interest of a High Dose of Erythropoietin Administered During Graft Processing for Early Graft Outcome in Kidney Transplant Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background : Numerous studies have outlined the cellular pleiotropic effects of&#xD;
      erythropoietin (EPO) and their role in the prevention of ischemic-reperfusion lesion such as&#xD;
      after acute ischemic injury of the brain or the heart. However, most of these studies were&#xD;
      carried out in animal models and no definitive proof exists today to demonstrate that EPO has&#xD;
      similar beneficial effects in human pathology.&#xD;
&#xD;
      Purpose : The aim of the study is to demonstrate that in humans, EPO can protect against&#xD;
      ischemic-reperfusion lesions in a model of ischemia i.e. kidney transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abstract : Since the discovery that EPO and its receptor are expressed in various tissues,&#xD;
      numerous studies have demonstrated that EPO is not only involved in erythropoiesis but also&#xD;
      exerts pleiotropic effects on cells. Among these, one of the most exciting is its role in the&#xD;
      prevention of ischemic-reperfusion lesions such as after acute ischemic injury of the brain&#xD;
      or the heart. However, most of these studies were carried out in animal models and no&#xD;
      definitive proof exists today to demonstrate that EPO has similar beneficial effects in human&#xD;
      pathology. Kidney transplantation is one ischemic situation where EPO pleiotropic effects&#xD;
      could be of great interest since ischemic-reperfusion lesions have been involved in delayed&#xD;
      graft function and impaired graft outcomes.&#xD;
&#xD;
      The aim of this prospective randomized double blind study is to assess the effect of 100 000&#xD;
      UI of béta-epoiétin on kidney graft function, given to the deceased donor one hour before the&#xD;
      retreaval of the organ. Recipients will be followed for three months in order to evaluate&#xD;
      kidney function (glomerular filtration rate) and the number of acute rejection episodes to&#xD;
      determine whether beta-epoietin could modify the immunogenicity of the graft.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of patients eligible for the study.&#xD;
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a plasma creatinin level</measure>
    <time_frame>5 days</time_frame>
    <description>To assess the effect of an injection of 100 000 UI of beta-epoitein during graft processing, on the proportion of renal recipients with a plasma creatinin level below 250 µM at day 5 after transplantation in the absence of hemodialysis, death or transplantectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of delayed graft function defined as follows:</measure>
    <time_frame>48 hours</time_frame>
    <description>The incidence of delayed graft function defined as follows: combination of the need for dialysis (except dialysis for hyperkalemia or volume overload) or creatinine reduction ratio of less than 25% within the first 48 h post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDRD glomerular filtration rate at one and three months</measure>
    <time_frame>three months</time_frame>
    <description>MDRD glomerular filtration rate at one and three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of acute rejection during the first three months</measure>
    <time_frame>three months</time_frame>
    <description>The incidence of acute rejection during the first three months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>Graft with EPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous 1000 000UI beta-epoietin one hour before organe retrieval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>graft without EPO</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no injection befoe organ retrieval</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beta-epoietin</intervention_name>
    <description>100 000UI beta-epoietin injection one hour before organ retrieval</description>
    <arm_group_label>Graft with EPO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  donor:&#xD;
&#xD;
               -  cadaveric organ donor,&#xD;
&#xD;
               -  age ≥ 18 years,&#xD;
&#xD;
               -  mono-organ (kidney) retrieval,&#xD;
&#xD;
               -  retrieval done in the centres of Limoges, Bordeaux, Toulouse, Angers, Brest,&#xD;
                  Nantes, Poitiers, Rennes, Tours,&#xD;
&#xD;
               -  hematocrit ≤ 45%.&#xD;
&#xD;
          -  Recipient:&#xD;
&#xD;
               -  age ≥ 18 years,&#xD;
&#xD;
               -  on the waiting list for a kidney graft.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  living donors,&#xD;
&#xD;
          -  age under 18 years,&#xD;
&#xD;
          -  multi-organ retrieval,&#xD;
&#xD;
          -  donor hematocrit above 45%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie ESSIG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU LIMOGES</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'ANGERS - CHPOT</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de BORDEAUX - CHPOT</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de BORDEAUX - Service de Néphrologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Brest</city>
        <zip>29 609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de BREST - CHPOT</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de LIMOGES - CHPOT</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de LIMOGES - Service de Néphrologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NANTES - CHPOT</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NANTES - Service de Néphrologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de POITIERS - CHPOT</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de RENNES - CHPOT</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de RENNES - Service de Néphrologie</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de TOULOUSE - CHPOT</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de TOULOUSE - Service de Néphrologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de TOURS - CHPOT</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high dose of EPO</keyword>
  <keyword>transplant kidney</keyword>
  <keyword>cadaveric organ donor</keyword>
  <keyword>mono-organ (kidney) retrieval</keyword>
  <keyword>patient</keyword>
  <keyword>kidney graft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

